The addition of ribavirin to 12 weeks of Harvoni showed little therapeutic benefit in patients undergoing retreatment for hepatitis C after failing to achieve sustained virologic response with a prior NS5A inhibitor-containing regimen, according to recently published data.
“Chronic hepatitis C virus (HCV) infection affects approximately 180 million people worldwide and is a major cause of chronic liver disease, which can progress to cirrhosis, with and without hepatocellular carcinoma (HCC),” Hiroki Ikeda, MD, from the St. Marianna University, Japan, and colleagues wrote. “Treatment of HCV infection has progressed rapidly since the development of direct acting antiviral-agents (DAAs).”
Ikeda and colleagues enrolled 29 patients with chronic HCV genotype 1b who had not achieved SVR after 24 weeks of therapy with Daklinza (daclatasvir, Bristol-Myers Squibb) and asunaprevir (Bristol-Myers Squibb). Patients received treatment with Harvoni (ledipasvir/sofosbuvir, Gilead Sciences) for 12 weeks; 15 patients also received ribavirin.